Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan

Published by: Datamonitor

Published: Nov. 2, 2009


Table of Contents


ABOUT DATAMONITOR HEALTHCARE
About the Infectious diseases pharmaceutical analysis team
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into vaccines in emerging markets (Asia)
Limitations
Related reports
Upcoming related reports
CHAPTER 1 OVERVIEW OF THE FOUR MAIN ASIAN EMERGING MARKETS FOR VACCINES
China and India offer a large, untapped demographic opportunity for vaccine makers
The increasing wealth in Asia has led to the emergence of a promising private sector market for vaccines
There is a promising opportunity for vaccines against endemic diseases in Asia
Vaccination coverage and recommendations vary across the key emerging Asian markets
There are significant differences regarding the general environment for vaccines in India, China, Taiwan and South Korea
CHAPTER 2 INDIA
Summary
General characteristics
Demographics
Economics
Healthcare expenditure and access
The Indian vaccines market
Historic development
Current market situation
Key stakeholders in India's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in India
General overview
Multinational corporations
GlaxoSmithKline
Sanofi Pasteur
Novartis
Wyeth, Merck & Co
Local vaccine players
Serum Institute of India
Biological E
Panacea Biotec
Shantha Biotechnics
Bharat Biotech
Bio-Med
Indian Immunologicals
Key future target indications
SWOT analysis of India as a target market for vaccine producers
Best strategy for market penetration
CHAPTER 3 CHINA
Summary
General characteristics
Demographics
Economics
Healthcare spend and access
The Chinese vaccines market
Historic development
Current market situation
Key stakeholders in China's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in China
General overview
Multinational corporations
GlaxoSmithKline
Sanofi Pasteur
Novartis, Wyeth, Merck & Co
Local vaccine players
China National Biotec Group (CNBG)
Sinovac
Key future target indications
SWOT analysis of China as a target market for vaccine producers
Best strategy for market penetration
CHAPTER 4 TAIWAN
Summary
General characteristics
Demographics
Economics
Healthcare spend and access
The Taiwanese vaccines market
Historic development
Current market situation
Key stakeholders in Taiwan's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in Taiwan
General overview
Multinational corporations
Wyeth
GlaxoSmithKline
Novartis
Local vaccine players
ADImmune
Key future target indications
SWOT analysis of Taiwan as a target market for vaccine producers
Best strategy for market penetration
CHAPTER 5 SOUTH KOREA
Summary
General characteristics
Demographics
Economics
Healthcare spend and access
The South Korean vaccines market
Historic development
Current market situation
Key stakeholders in South Korea's vaccination system
Existing recommendations, coverage, available vaccines
Vaccination recommendations
Vaccination coverage
Available vaccines
Regulatory process for vaccines
Key vaccine players in South Korea
General overview
Multinational corporations
GlaxoSmithKline, Sanofi Pasteur
Merck & Co
Novartis
Crucell
Local vaccine players
Korea Vaccine
SK Chemicals
Green Cross Korea
Key future target indications
SWOT analysis of South Korea as a target market for vaccine producers
Best strategy for market penetration
BIBLIOGRAPHY
Literature
APPENDIX
Contributing experts
Key opinion leaders
Conferences
Report methodology
About Datamonitor
About Datamonitor Healthcare
About the Infectious Diseases analysis team
Key therapy team members
Holger Rovini, Head of Respiratory and Infectious Diseases
Hedwig Kresse, Senior Analyst, Infectious Diseases
Disclaimer
List of Tables
Table 1: Overview: Vaccines recommended as part of the national immunization schedule in India, China, Taiwan and South Korea, 2009
Table 2: India: key economic indicators, 2006-08
Table 3: India: healthcare expenditure indicators, 2006
Table 4: India: key health system indicators, 2006
Table 5: India: top 10 causes of mortality, 2004
Table 6: India: estimated number of vaccine doses distributed for key indications, 2009
Table 7: India: vaccination recommendations by the National Immunization Program (NIP) and the Indian Academy of Pediatrics (IAP), 2009
Table 8: India: top 10 vaccines by sales, 2008, as reported by MIDAS sales data, IMS Health, 2009
Table 9: India: biotech turnover of key vaccine players, 2003/04 and 2004/05
Table 10: India: position of the five key Western vaccine players, 2009
Table 11: India: key local vaccine manufacturers, 2009
Table 12: Serum Institute of India: human vaccine portfolio and pipeline overview, 2009
Table 13: Serum Institute of India: key vaccine deals and alliances, 2009
Table 14: Biological E: vaccine portfolio and pipeline overview, 2009
Table 15: Biological E: key vaccine deals and alliances, 2009
Table 16: Panacea Biotec: human vaccine portfolio and pipeline overview, 2009
Table 17: Panacea Biotec: key vaccine deals and alliances, 2009
Table 18: Shantha Biotechnics: human vaccine portfolio and pipeline overview, 2009
Table 19: Shantha Biotechnics: key vaccine deals and alliances, 2009
Table 20: Bharat Biotech: vaccine portfolio and pipeline overview, 2009
Table 21: Bharat Biotech: key vaccine deals and alliances, 2009
Table 22: Bio Med: vaccine portfolio and pipeline overview, 2009
Table 23: Indian Immunologicals: human vaccine portfolio and pipeline overview, 2009
Table 24: SWOT analysis of India as vaccine market, 2009
Table 25: China: key economic indicators, 2006-08
Table 26: China: healthcare expenditure indicators, 2006
Table 27: China: key health system indicators, 2006
Table 28: China: top 10 causes of mortality, 2004
Table 29: China: estimated number of vaccine doses distributed for key indications, 2009
Table 30: China: vaccination recommendations, 2009
Table 31: China: top 10 vaccines by sales, 2008, as reported by MIDAS sales data, IMS Health, 2009
Table 32: China: position of the five key Western vaccine players, 2009
Table 33: China: key local vaccine manufacturers, 2009
Table 34: China National Biotec Group: human vaccine portfolio and pipeline overview, 2009
Table 35: China National Biotec Group: key vaccine deals and alliances, 2009
Table 36: Sinovac: human vaccine portfolio and pipeline overview, 2009
Table 37: Sinovac: key vaccine deals and alliances, 2009
Table 38: SWOT analysis of China as vaccine market, 2009
Table 39: Taiwan: key economic indicators, 2006-08
Table 40: Taiwan: healthcare expenditure indicators, 2005
Table 41: Taiwan: top 10 causes of mortality, 2006
Table 42: Taiwan: estimated number of vaccine doses distributed for key indications, 2009
Table 43: Taiwan: vaccination recommendations, 2009
Table 44: Taiwan: top 10 vaccines by sales, 2008, as reported by MIDAS sales data, IMS Health, 2009
Table 45: Taiwan: position of the five key Western vaccine players, 2009
Table 46: ADImmune: human vaccine portfolio and pipeline overview, 2009
Table 47: ADImmune: key vaccine deals and alliances, 2009
Table 48: SWOT analysis of Taiwan as vaccine market, 2009
Table 49: South Korea: key economic indicators, 2006-08
Table 50: South Korea: healthcare expenditure indicators, 2006
Table 51: South Korea: key health system indicators, 2006
Table 52: South Korea: top 10 causes of mortality, 2004
Table 53: South Korea: estimated number of vaccine doses distributed for key indications, 2009
Table 54: South Korea: vaccination recommendations, 2009
Table 55: South Korea: top 10 vaccines by sales, 2008, as reported by MIDAS sales data, IMS Health, 2009
Table 56: South Korea: classification of vaccines according to origin
Table 57: South Korea: position of the five key Western vaccine players, 2009
Table 58: South Korea: key local vaccine manufacturers, 2009
Table 59: Korea Vaccine: human vaccine portfolio overview, 2009
Table 60: SK Chemicals: human vaccine portfolio overview, 2009
Table 61: SK Chemicals: key vaccine deals and alliances, 2009
Table 62: Green Cross Korea: human vaccine portfolio and pipeline overview, 2009
Table 63: Green Cross Korea: key vaccine deals and alliances, 2009
Table 64: SWOT analysis of South Korea as vaccine market, 2009
List of Figures
Figure 1: Overview: Total population size, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
Figure 2: Overview: Birth cohort size, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
Figure 3: Overview: Gross domestic product per capita, India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
Figure 4: Overview: Healthcare spend per capita and private expenditure on health in India, China, Taiwan, South Korea, the US and the 5EU, 1994-2019
Figure 5: Overview: Distribution of key endemic diseases in Asia
Figure 6: Overview: Coverage for key vaccinations in India, China, Taiwan and South Korea, 2008
Figure 7: Overview: Estimates of the market size for human vaccines in India, China, Taiwan and South Korea, 2009
Figure 8: Overview: Key domestic vaccine players in India, China, Taiwan and South Korea, 2009
Figure 9: Overview: Key vaccine market characteristics in India, China, Taiwan and South Korea, 2009
Figure 10: India: overview of the vaccine landscape, 2009
Figure 11: India: population growth, 1994-2019
Figure 12: India: population spread by age group, 2009 versus 2019
Figure 13: India: mortality of children <5 years of age, 1994-2019
Figure 14: India: key stakeholders in administering Universal Immunization Program (UIP) vaccines, 2009
Figure 15: India: National Immunization Program (NIP) vaccination schedule, 2009
Figure 16: India: Indian Academy of Pediatrics (IAP) vaccination schedule, 2009
Figure 17: India: vaccination coverage, 2002-04 versus 2007-08
Figure 18: India: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 19: India: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class , 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 20: India: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 21: India: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
Figure 22: India: key future target vaccine indications, 2009
Figure 23: China: overview of the vaccine landscape, 2009
Figure 24: China: population growth, 1994-2019
Figure 25: China: population spread by age group, 2009 versus 2019
Figure 26: China: mortality of children <5 years of age, 1994-2019
Figure 27: China: vaccination schedule, 2009
Figure 28: China: vaccination coverage, 2004-08
Figure 29: China: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 30: China: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 31: China: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 32: China: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
Figure 33: China National Biotec Group: organization structure
Figure 34: China: key future target vaccine indications, 2009
Figure 35: Taiwan: overview of the vaccine landscape, 2009
Figure 36: Taiwan: development of population size, 1994-2019
Figure 37: Taiwan: population spread by age group, 2009 versus 2019
Figure 38: Taiwan: mortality of children <5 years of age, 1994-2019
Figure 39: Taiwan: vaccination schedule, 2009
Figure 40: Taiwan: vaccination coverage, 2009
Figure 41: Taiwan: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 42: Taiwan: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 43: Taiwan: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 44: Taiwan: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
Figure 45: Taiwan: key future target vaccine indications, 2009
Figure 46: South Korea: overview of the vaccine landscape, 2009
Figure 47: South Korea: population growth, 1994-2019
Figure 48: South Korea: population spread by age group, 2009 versus 2019
Figure 49: South Korea: mortality of children <5 years of age, 1994-2019
Figure 50: South Korea: vaccination schedule, 2009
Figure 51: South Korea: vaccination coverage, 2004-08
Figure 52: South Korea: vaccine sales by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 53: South Korea: vaccine volume use by Anatomical Therapeutic Chemical (ATC) class, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 54: South Korea: market share of total vaccine sales for local and multinational vaccine manufacturers, 2004-08, as reported by MIDAS sales data, IMS Health, 2009
Figure 55: South Korea: market share of total vaccine sales by company, 2008, as reported by MIDAS sales data, IMS Health, 2009
Figure 56: South Korea: vaccine imports versus local manufacturing, 2009
Figure 57: South Korea: key future target vaccine indications, 2009

Abstract

Introduction

Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. However, facing increasingly saturated markets in the West, companies are looking to expand into new geographies, such as Asia's emerging markets.

Scope
  • Strategic analysis of key domestic vaccine companies as well as the position of major international players
  • Thorough assessment of the market environment for vaccines in India, China, Taiwan and Korea
  • Review of existing vaccine recommendations, coverage rates and promising future indications
  • In-depth discussion of strengths, weaknesses, opportunities and threats for each market from a vaccine maker's perspective
Highlights

Immunizations in India are currently restricted to a limited public vaccination schedule, with the insufficient healthcare infrastructure in rural areas contributing to low coverage rates. Commercial opportunities lie in providing premium vaccines to the emerging private sector and in partnering with domestic players.

China is a very challenging market for international vaccine companies. The country remains difficult to penetrate due to the high language and cultural barriers, opaque regulatory environment and strong government influence. Local expertise and connections are crucial, making partnerships with domestic players a key strategy for market access.

With only one domestic vaccine player, Taiwan relies on imports. Looking to decrease the country's reliance on imports and to establish it as a hub for biotechnology, the Taiwanese government is encouraging international vaccine makers to build manufacturing and R&D facilities in the country, offering tax rebates and advance purchase agreements.

Reasons to Purchase
  • Review portfolios and deals for key domestic vaccine companies as well as the position of major international vaccine makers
  • Gain insight into the market environment for vaccines through a review of demographic, economic and regulatory trends
  • Understand challenges, unmet needs and future opportunities by learning about the views of key opinion leaders from each country
Please note: this is delivered as a Zip file.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2010